Eli Lilly Obesity Therapy Succeeds in Late-Stage Trials for Sleep Disorder

1
Comment
Favorite

Eli Lilly Obesity Therapy Succeeds in Late-Stage Trials for Sleep Disorder

seekingalpha04-17

Eli Lilly announced Wednesday that its weight loss therapy, tirzepatide, reached main goals in two Phase 3 trials for patients with obesity and obstructive sleep apnea (OSA), a sleep-related breathing...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

iNkwiziTs
·04-17
Wow 😍
Reply
4
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1178828108?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-17 20:42","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1178828108","market":"us","top_or_hot":-1,"title":"Eli Lilly Obesity Therapy Succeeds in Late-Stage Trials for Sleep Disorder","media":"seekingalpha","content":"<div>\n<p>Eli Lilly announced Wednesday that its weight loss therapy, tirzepatide, reached main goals in two Phase 3 trials for patients with obesity and obstructive sleep apnea (OSA), a sleep-related breathing...</p>\n\n<a href=\"https://seekingalpha.com/news/4090375-eli-lilly-stock-gains-zepbound-succeeds-sleep-apnea\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly Obesity Therapy Succeeds in Late-Stage Trials for Sleep Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly Obesity Therapy Succeeds in Late-Stage Trials for Sleep Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-17 20:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4090375-eli-lilly-stock-gains-zepbound-succeeds-sleep-apnea><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly announced Wednesday that its weight loss therapy, tirzepatide, reached main goals in two Phase 3 trials for patients with obesity and obstructive sleep apnea (OSA), a sleep-related breathing...</p>\n\n<a href=\"https://seekingalpha.com/news/4090375-eli-lilly-stock-gains-zepbound-succeeds-sleep-apnea\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"https://seekingalpha.com/news/4090375-eli-lilly-stock-gains-zepbound-succeeds-sleep-apnea","article_id":"1178828108","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178828108","pubTimestamp":1713357740,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Eli Lilly announced Wednesday that its weight loss therapy, tirzepatide, reached main goals in two Phase 3 trials for patients with obesity and obstructive sleep apnea (OSA), a sleep-related breathing","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"礼来公司肥胖疗法在睡眠障碍的后期试验中取得成功","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1.1},"content_text":"Eli Lilly announced Wednesday that its weight loss therapy, tirzepatide, reached main goals in two Phase 3 trials for patients with obesity and obstructive sleep apnea (OSA), a sleep-related breathing disorder.Eli Lilly stock jumps 2.6% in premarket trading.Citing topline data, the Indiana-based pharma giant said tirzepatide, marketed as Zepbound, significantly reduced the apnea-hypopnea index (AHI), trials' primary endpoints, compared to placebo.Lilly's SURMOUNT-OSA program, which involved 469 adults with moderate-to-severe OSA and obesity across multiple countries, also reached a key secondary endpoint based on the percentage change in AHI, the company said.In SURMOUNT-OSA Study 1, which involved those who were not on positive airway pressure (PAP) therapy, tirzepatide led to a mean AHI reduction of 27.4 events per hour compared to 4.8 events per hour for placebo at 52 weeks.In SURMOUNT-OSA Study 2, for those on PAP therapy, the dual GIP and GLP-1 receptor agonist led to a mean AHI reduction from baseline of 30.4 events per hour compared to 6.0 events per hour for placebo.The injectable led to a nearly 20% weight loss at 52 weeks across both trials, where 70% of trial subjects were males, who are, compared to females, less responsive to incretin therapy such as tirzepatide.Most of the adverse events were found to be gastrointestinal-related and generally mild to moderate in severity, Eli Lilly (LLY) said.The company intends to submit SURMOUNT-OSA data for publication in a peer-reviewed journal and share the results with regulators, including the FDA, beginning in mid-2024.Stocks to watch include CPAP device makers ResMed (RMD), Inspire Medical Systems (INSP) and Philips (PHG), as well as sleep apnea drug developer Jazz Pharmaceuticals (JAZZ).Eli Lilly and its Danish rival Novo Nordisk (NVO) dominate the market for weight loss therapies with their FDA-approved GLP-1 agonists, tirzepatide, and semaglutide.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[{"id":296224849629320,"gmtCreate":1713358037293,"gmtModify":1713358040650,"author":{"id":"3569473957254831","authorId":"3569473957254831","name":"iNkwiziTs","avatar":"https://static.tigerbbs.com/7cfab89f2382be8e231dff17c4383110","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":7,"crmLevelSwitch":1},"htmlText":"Wow 😍","listText":"Wow 😍","text":"Wow 😍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/296224849629320","repostId":1178828108,"repostType":4,"repost":{"id":"1178828108","pubTimestamp":1713357740,"share":"https://www.laohu8.com/m/news/1178828108?lang=&edition=full","pubTime":"2024-04-17 20:42","market":"us","language":"en","title":"Eli Lilly Obesity Therapy Succeeds in Late-Stage Trials for Sleep Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=1178828108","media":"seekingalpha","summary":"Eli Lilly announced Wednesday that its weight loss therapy, tirzepatide, reached main goals in two Phase 3 trials for patients with obesity and obstructive sleep apnea (OSA), a sleep-related breathing","content":"<html><head></head><body><p>Eli Lilly announced Wednesday that its weight loss therapy, tirzepatide, reached main goals in two Phase 3 trials for patients with obesity and obstructive sleep apnea (OSA), a sleep-related breathing disorder.</p><p>Eli Lilly stock jumps 2.6% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/f38ae75be6747701e91c190bb7feebbc\" tg-width=\"772\" tg-height=\"624\"/></p><p style=\"text-align: left;\">Citing topline data, the Indiana-based pharma giant said tirzepatide, marketed as Zepbound, significantly reduced the apnea-hypopnea index (AHI), trials&#39; primary endpoints, compared to placebo.</p><p style=\"text-align: left;\">Lilly&#39;s SURMOUNT-OSA program, which involved 469 adults with moderate-to-severe OSA and obesity across multiple countries, also reached a key secondary endpoint based on the percentage change in AHI, the company said.</p><p style=\"text-align: left;\">In SURMOUNT-OSA Study 1, which involved those who were not on positive airway pressure (PAP) therapy, tirzepatide led to a mean AHI reduction of 27.4 events per hour compared to 4.8 events per hour for placebo at 52 weeks.</p><p style=\"text-align: left;\">In SURMOUNT-OSA Study 2, for those on PAP therapy, the dual GIP and GLP-1 receptor agonist led to a mean AHI reduction from baseline of 30.4 events per hour compared to 6.0 events per hour for placebo.</p><p style=\"text-align: left;\">The injectable led to a nearly 20% weight loss at 52 weeks across both trials, where 70% of trial subjects were males, who are, compared to females, less responsive to incretin therapy such as tirzepatide.</p><p style=\"text-align: left;\">Most of the adverse events were found to be gastrointestinal-related and generally mild to moderate in severity, Eli Lilly (LLY) said.</p><p style=\"text-align: left;\">The company intends to submit SURMOUNT-OSA data for publication in a peer-reviewed journal and share the results with regulators, including the FDA, beginning in mid-2024.</p><p style=\"text-align: left;\">Stocks to watch include CPAP device makers ResMed (RMD), Inspire Medical Systems (INSP) and Philips (PHG), as well as sleep apnea drug developer Jazz Pharmaceuticals (JAZZ).</p><p style=\"text-align: left;\">Eli Lilly and its Danish rival Novo Nordisk (NVO) dominate the market for weight loss therapies with their FDA-approved GLP-1 agonists, tirzepatide, and semaglutide.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly Obesity Therapy Succeeds in Late-Stage Trials for Sleep Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly Obesity Therapy Succeeds in Late-Stage Trials for Sleep Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-17 20:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4090375-eli-lilly-stock-gains-zepbound-succeeds-sleep-apnea><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly announced Wednesday that its weight loss therapy, tirzepatide, reached main goals in two Phase 3 trials for patients with obesity and obstructive sleep apnea (OSA), a sleep-related breathing...</p>\n\n<a href=\"https://seekingalpha.com/news/4090375-eli-lilly-stock-gains-zepbound-succeeds-sleep-apnea\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来"},"source_url":"https://seekingalpha.com/news/4090375-eli-lilly-stock-gains-zepbound-succeeds-sleep-apnea","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1178828108","content_text":"Eli Lilly announced Wednesday that its weight loss therapy, tirzepatide, reached main goals in two Phase 3 trials for patients with obesity and obstructive sleep apnea (OSA), a sleep-related breathing disorder.Eli Lilly stock jumps 2.6% in premarket trading.Citing topline data, the Indiana-based pharma giant said tirzepatide, marketed as Zepbound, significantly reduced the apnea-hypopnea index (AHI), trials' primary endpoints, compared to placebo.Lilly's SURMOUNT-OSA program, which involved 469 adults with moderate-to-severe OSA and obesity across multiple countries, also reached a key secondary endpoint based on the percentage change in AHI, the company said.In SURMOUNT-OSA Study 1, which involved those who were not on positive airway pressure (PAP) therapy, tirzepatide led to a mean AHI reduction of 27.4 events per hour compared to 4.8 events per hour for placebo at 52 weeks.In SURMOUNT-OSA Study 2, for those on PAP therapy, the dual GIP and GLP-1 receptor agonist led to a mean AHI reduction from baseline of 30.4 events per hour compared to 6.0 events per hour for placebo.The injectable led to a nearly 20% weight loss at 52 weeks across both trials, where 70% of trial subjects were males, who are, compared to females, less responsive to incretin therapy such as tirzepatide.Most of the adverse events were found to be gastrointestinal-related and generally mild to moderate in severity, Eli Lilly (LLY) said.The company intends to submit SURMOUNT-OSA data for publication in a peer-reviewed journal and share the results with regulators, including the FDA, beginning in mid-2024.Stocks to watch include CPAP device makers ResMed (RMD), Inspire Medical Systems (INSP) and Philips (PHG), as well as sleep apnea drug developer Jazz Pharmaceuticals (JAZZ).Eli Lilly and its Danish rival Novo Nordisk (NVO) dominate the market for weight loss therapies with their FDA-approved GLP-1 agonists, tirzepatide, and semaglutide.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}